In January, the first patient was enrolled in Phase I clinical trial for MIL95 (CD47 antibody);

In April, the first patient was enrolled in Phase I clinical trial for MIL93 (Claudin 18.2 antibody);

In May, we filed IND application to NMPA for MIL97 (CD40 antibody), and we obtained IND approval from NMPA for MIL62 (Third-generation CD20 antibody) to treat PMN

In June, the first patient was enrolled in Phase III clinical trial for MIL62 for the treatment of relapsed/refractory FL
We completed investments undertaken by, among others, Tigermed and WuXi Biologics.

In May, we completed the Phase III trial for MIL60 (Bevacizumab biosimilar) and filed the NDA application in June;
we obtained IND approval from NMPA for MIL95 (CD47 antibody);

In July, the first patient was enrolled in Phase I/IIa clinical trial for the combination of MIL62 (Third-generation CD20 antibody) with BTK inhibitor;

In August, the first patient was enrolled in Phase I clinical trial for MBS301 (HER2/HER2 bispecific antibody);

In October, we obtained IND approval from NMPA for MIL93 (Claudin 18.2 antibody);

In December, we obtained IND approval from NMPA for MIL62 to treat LN;
We completed investments undertaken by, among others, CICC Capital, CITIC Investment, LYZZ Capital, SDIC and Lake Bleu Capital.

In March, we signed a collaboration agreement with InnoCare (stock code: 09969.HK) regarding the combination of MIL62 (Third-generation CD20 antibody) with BTK inhibitor, and obtained IND approval from NMPA for the combination therapy in August;

In April, we obtained IND approval from NMPA for MIL86 (PCSK9 antibody);

In September, we filed a PCT patent application for MIL93 (Claudin 18.2 antibody);

In October, we filed a PCT patent application for MIL97 (CD40 antibody);

In November, the first patient was enrolled in Phase II clinical trial for MIL62 for the treatment of relapsed/refractory FL;
We completed investments undertaken by, among others, CASVC and E-Town International Investment.

In January, we signed a collaboration agreement with Keymed (stock code: 02162.HK) regarding the development of MIL95 (CD47 antibody).

In March, we signed a collaboration agreement with Betta (stock code: 300558.SZ) to develop, manufacture and commercialize MIL60 (Bevacizumab biosimilar), and the Phase III clinical trial for MIL60 was initiated in August;

In July, we filed a PCT patent application for MBS301 (HER2/HER2 bispecific antibody);
In August, we filed a PCT patent application for MIL62 (Third-generation CD20 antibody).

In October, we obtained IND approval from NMPA for our core product MIL62 (Third-generation CD20 antibody) for the treatment of relapsed/refractory B-cell lymphoma;
We completed investments undertaken by, among others, GIG and Harvest Investments.